“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning of the sector’s longevity and will be what leads the recovery from the current position,” declared Chris Hollowood, CEO of UK life sciences investment firm Syncona Investment Management Limited, summing up a view that is held by many in the sector.
“This optimism is rooted in our belief that the industry is now at a critical juncture, where the tools we...
